Navigation Links
Perrigo Reports Record Fourth Quarter and Fiscal Year Revenue, Earnings and Cash Flow From Operations
Date:8/16/2012

ALLEGAN, Mich., Aug. 16, 2012 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO; TASE) today announced results for its fourth quarter and full year ended June 30, 2012.

(Logo:  http://photos.prnewswire.com/prnh/20120301/DE62255LOGO )

Perrigo's Chairman and CEO Joseph C. Papa commented, "For the sixth straight year, we delivered year-over-year record sales and earnings while continuing to make investments in our facilities and production processes which we believe will further enhance our own already high standards of excellent product quality. During this fiscal year, we also announced the acquisition of CanAm Care to broaden our diabetes category offerings, multiple supply agreements for infant formula in China and numerous new product launches. The penetration of store brand share in the U.S. market continues to gain momentum as retailers and patients continue to turn to high quality, affordable alternatives for their healthcare needs. We look forward to another great year, with many new products in the pipeline across all segments."

Refer to Table I at the end of this press release for adjustments in the current year and prior year periods and additional non-GAAP disclosure information.

The Company's reported results are summarized in the attached Consolidated Statements of Income, Balance Sheets and Cash Flows.Perrigo Company
(from continuing operations, in thousands, except per share amounts)
(see the attached Table I for reconciliation to GAAP numbers)

 Fourth Quarter

Fiscal Year2012

2011

2012

2011Net Sales

$831,767

$704,629

$3,173,249

$2,755,029Reported Income

$107,050

$85,570

$392,974

$340,558Adjusted Income

$120,946

$95,418
'/>"/>

SOURCE Perrigo Company
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related biology technology :

1. Perrigo Receives FDA Approval And Commences Launch Of Morphine Sulfate 100ml/5% Oral Solution
2. China Biologic Reports Financial Results for the Second Quarter and First Half of 2012
3. BioSpecifics Technologies Corp. Reports Second Quarter 2012 Financial Results
4. Avanir Pharmaceuticals Reports Fiscal 2012 Third Quarter Financial And Business Results
5. Savient Pharmaceuticals Reports Second Quarter 2012 Financial Results
6. Origin Agritech Limited Reports Unaudited Third Quarter Financial Results For Three Months Ended June 30, 2012
7. Verenium Reports Financial Results For The Second Quarter And Six Months Ended June 30, 2012
8. Cadence Pharmaceuticals Reports Second Quarter 2012 Financial Results
9. Discovery Labs Reports Second Quarter 2012 Financial Results
10. Haemonetics Reports First Quarter Fiscal 2013 Results, Completes Acquisition of Palls Transfusion Medicine Business, Affirms Fiscal 2013 Earnings Guidance, Provides Preliminary Outlook for Fiscal 2014 and Announces Share Repurchase
11. Cambrex Reports Second Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... June 18, 2013 ... announced the addition of the report " ... " to their offering.      ... reviews basics of human genome variations, development ... large and small sequencers are described as ...
(Date:6/18/2013)... 2013   Lexicon Pharmaceuticals, Inc. (Nasdaq: ... on discovering breakthrough treatments for human disease, announced ... the company as its vice president of marketing, ... commercial experience to Lexicon, including both pre-launch planning ... areas. Mr. Northcott has held commercial ...
(Date:6/18/2013)... DUBLIN , June 18, 2013 ... Markets ( http://www.researchandmarkets.com/research/cmbgcv/north_american ) has announced ... American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes ... Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, ... to 2017" report to their ...
(Date:6/18/2013)... June 18, 2013 Inflamax Research ... of Concept and Phase I-IV clinical trials, announced ... with Northern Air Environmental Technologies (NAET), a specialty ... deployment, monitoring, and servicing of mobile Environmental Exposure ... clinical trials. , Inflamax Research ...
Breaking Biology Technology:DNA Sequencing: Technologies, Markets and Companies - 2013 Report 2John Northcott Joins Lexicon as Vice President of Marketing, Commercial Strategy and Operations 2John Northcott Joins Lexicon as Vice President of Marketing, Commercial Strategy and Operations 3North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market - Forecast to 2017 2North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market - Forecast to 2017 3Inflamax Research Inc. Enters Strategic Partnership with Northern Air Environmental Technologies Inc. 2Inflamax Research Inc. Enters Strategic Partnership with Northern Air Environmental Technologies Inc. 3
... CLAREMONT, Calif.*, May 19 /Xinhua-PRNewswire-FirstCall/ --,Kiwa Bio-Tech Products ... Beijing Hai Xin Science and Technology Co., Ltd.,("Hai ... This,May, the Board Chairman of Hai Xin, Mr. ... Kiwa,s Beijing headquarters., Hai Xin is a ...
... Digital Radiography, PACS and Practice Management Software Adds ... Philips Ultrasound ... Eklin Medical Systems, a,leading developer of digital radiography (DR), ... (VIA(TM)) for,veterinary care practices, announced it has completed its ...
... May 19 Replikins Ltd. has found that ... found in the,trypanosomes that are the infectious agents ... in fact the highest replikin concentrations observed to,date ... also found that these,concentrations cycle over several years., ...
Cached Biology Technology:Kiwa Bio-Tech in Collaboration Discussions with Beijing Hai Xin Science and Technology Co., Ltd. 2Kiwa Bio-Tech in Collaboration Discussions with Beijing Hai Xin Science and Technology Co., Ltd. 3Eklin Announces Acquisition of Ultrasource, Inc. 2Eklin Announces Acquisition of Ultrasource, Inc. 3Highest Replikin Concentrations and Cyclical Behavior Related to Human Mortality Are Found in Malaria Trypanosomes 2
(Date:6/18/2013)... of DNA and this modification can occur in ... now, scientists believed that this epigenetic phenomenon actively ... team of researchers from the University of Geneva ... at the Faculty of Medicine, reveals that this ... methylation may play both a passive and active ...
(Date:6/17/2013)... patients with severe brain infections in Vietnam. Further research ... for the symptoms of disease. , The virus was ... patients with severe brain infections in the study, corresponding ... 122 patients with non-infectious brain disorders that were tested. ... are often fatal and patients who do survive, often ...
(Date:6/17/2013)... improving original foundations with more modern elements. Using this ... Kenneth P. Dietrich School of Arts and Sciences have ... delivery, gas storage, and gas transport more efficient and ... the latest issue of the Journal of the ... recent work builds upon Pitt Associate Professor of Chemistry ...
Breaking Biology News(10 mins):The secret of DNA methylation 2New virus isolated from patients with severe brain infections 2New virus isolated from patients with severe brain infections 3'Chemical architects' build materials with potential applications in drug delivery and gas storage 2
... 13, 2011   Fate Therapeutics, Inc. announced ... trial of ProHema (FT1050-enhanced umbilical cord blood) as ... adult patients with hematologic malignancies who have undergone ... at the 53rd annual American Society of Hematology ...
... least one person admits that the extreme heat in Texas this year ... a handmade torture chamber. ... about the heat, but from my viewpoint as a breeder, I love ... maximum mean highs of 107 degrees for weeks near Mansfield and 104 ...
... have found an explanation for how the intestinal tract ... prevent infection, offering a potential clue to the cause ... "The findings shed light on the complex balance ... Prof. Jennifer Gommerman, an Associate Professor in the Department ...
Cached Biology News:Fate Therapeutics Announces Promising Data From Phase 1b Study of ProHema at the 2011 American Society of Hematology Annual Conference 2Fate Therapeutics Announces Promising Data From Phase 1b Study of ProHema at the 2011 American Society of Hematology Annual Conference 3Fate Therapeutics Announces Promising Data From Phase 1b Study of ProHema at the 2011 American Society of Hematology Annual Conference 4Rose torture: severe heat in Texas yields better varieties for research 2Intestine crucial to function of immune cells, research shows 2Intestine crucial to function of immune cells, research shows 3
... Provides a buffered anti-freeze environment for ... Maintains a liquid, low viscosity solution at ... is necessary and sampling is convenient ... during long-term storage Protect enzyme conjugates ...
A collection of 42 spots with normal tissues from different organs of C57 mice, rat and human....
... The V-106 voice-coil scanning and ... where small samples have to be ... and high resolution. It provides superior ... leadscrew drives. The mechanics (X or ...
Improves spot morphology and DNA binding to the slide resulting in increased hybridization signal. ID Clarifier: Optimized spotting solution for use with SigmaScreen APS Coated Slides for Microarrays...
Biology Products: